The year 2017 was the second year supporting our 2020 Supply Chain Environmental Sustainability Goals. We have an extensive supply chain, ranging from suppliers of general commodities to specialized active pharmaceutical ingredient manufacturers. All are expected to adhere to Pfizer’s supplier code of conduct and align with the PSCI principles. In addition, we have chosen to engage with a subset of our key suppliers to advance our environmental sustainability program. One hundred and fifty-eight suppliers were part of the 2017 survey and we have seen progress made on all elements of the 2020 Goal, including managing environmental impacts and instituting sustainability reduction goals.

Transforming Our Approach to Clinical Trials Clinical trials have long been the most time-consuming, complex and expensive element of drug development. Today’s leaps in technology and ‘big data’ analytics, combined with breakthroughs in the understanding and medical application of human biology, are radically transforming the way drugs are developed; however, new methodologies must preserve the paramount goals of protecting patients and evaluating potential risks as well as benefits. Pfizer is seeking to modernize clinical trials by pursuing what Rod MacKenzie, Pfizer’s Chief Development Officer, calls ‘extreme optimization.’ He explains: “We have one big job

It centers on the unique relationship between grandparents and grandchildren in Europe and the importance of protecting your heroes. In France, Precious Moments demonstrates the importance of vaccination to new parents through an engaging and relatable narrative

It centers on the unique relationship between grandparents and grandchildren in Europe and the importance of protecting your heroes. In France, Precious Moments demonstrates the importance of vaccination to new parents through an engaging and relatable narrative

An innovative partnership with the International Rescue Committee that provides access to vital health interventions by creating a one-stop-shop for the delivery of immunization and family planning services. Through a collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation we are working to help broaden access to Pfizer’s long-acting injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. Since the collaboration launched, with the help of a consortium of organizations from both the private and public sectors, more than 16 million units have been shipped across 23 countries in the developing world, potentially reaching more than 4 million women

PLEASE FOLLOW THE LINK BELOW FOR THE FULL PFIZER 2017 REPORT:-

https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2017/assets/pdf/pfizer-2017-annual-review.pdf